#Flaura2

#FLAURA2 analysis of exploratory subgroups shows mOS benefit in:

🧠 brain mets (40.9 v 29.7months)
🥃liver mets (36.6 vs 28months)
🦴bone mets (40.2 va 32.3 months)
🧬ctDNA positive (38.4 vs 32.5 months)

Confirms #FLAURA2 approch valid as a SOC in these groups #ESMO25 #LCSM

🫁 在今年 #WCLC2025（世界肺癌大會）上，FLAURA-2 試驗正式公布：針對 EGFR 突變晚期肺癌，osimertinib 加化療的中位存活期達 47.5 個月，比單藥多近 10 個月，四年整體存活率也從 41% 提升至 49%。

雖然令人振奮，但對臨床工作者來說並不意外。

在第三代標靶藥物尚未納入台灣健保時，我常建議病人使用第二代標靶藥物搭配口服化療，存活期與第三代相近。

FLAURA-2 的結果，驗證了這些年我們在資源有限情境下的臨床直覺與策略。

#肺癌 #臨床觀察 #藥物策略 #FLAURA2 #EGFR

At #WCLC25 results of #FLAURA2 showed a 47.5 mo mOS w/ osimertinib+chemo in pts w/ advanced EGFRm+ NSCLC vs 37.6 with osi monotherapy. Benefit seen across subgroups. Longer chemo-free period with combo. #LCSM #LungCancer #NSCLC #oncsky #cansky

WCLC 2025 Highlights: FLAURA2 trial - OncoDaily WCLC 2025 Highlights: FLAURA2 trial / Alessio Cortellini, Alfredo Addeo, Amit Kulkarni, Amol Akhade, Ana I. Velázquez Mañana, Antonio Calles, Bartomeu

WCLC 2025 Highlights: FLAURA2 trial

@iaslc.bsky.social

oncodaily.com/insight/wclc...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #WCLC #WCLC25 #FLAURA2 #IASLC

Frontline Osimertinib Plus Chemo Significantly Improves OS in EGFR-Mutated Advanced NSCLC Updated FLAURA2 OS data confirm osimertinib plus chemotherapy as a first-line SOC treatment in EGFR-mutated advanced NSCLC.

Frontline Osimertinib Plus Chemo Significantly Improves OS in EGFR-Mutated Advanced NSCLC
#FLAURA2 #NSCLC #WCLC25 @iaslc.bsky.social www.onclive.com/view/frontli...

The median overall survival of nearly 4 years appears to be the longest benefit ever reported in a global Phase III clinical trial #FLAURA2 in EGFR-mutated advanced lung cancer #WCLC25 #NSCLC #lcsm #medsky #biosky

AstraZeneca's cancer drug Tagrisso in combination w/ chemotherapy showed median overall survival/OS of nearly 4 yrs in Phase 3 trial #FLAURA2 in EGFR-mutated advanced non-small cell lung cancer. Below is Penn Medicine medical oncologist & #lcsm expert's tweets from #WCLC25 #NSCLC #medsky #biosky

FLAURA2 Trial: Osimertinib + Chemotherapy Enhances Survival FLAURA2 trial results show that osimertinib+chemotherapy significantly improves PFS and OS in patients with EGFR-mutated advanced NSCLC.

AstraZeneca’s Press Release: FLAURA2 trials results- Osimertinib Plus Chemotherapy Improves NSCLC Survival

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AstraZeneca #FLAURA2 #NSCLC #LungCancer #Osimertinib

Stephen V Liu: Positive Update from FLAURA2 Trial on EGFR NSCLC Treatment - OncoDaily Stephen V Liu: Positive Update from FLAURA2 Trial on EGFR NSCLC Treatment / cancer, EGFR+ NSCLC, NSCLC, OncoDaily, Oncology, Stephen V Liu

Positive Update from FLAURA2 Trial on EGFR NSCLC Treatment - Stephen V Liu
@stephenvliu.bsky.social

oncodaily.com/opinion/step...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FLAURA2 #EGFR #NSCLC

Dr. @LeXiuning now presenting #EGFR and #HER2 targeted therapies -new development and changing landscapes at our Targeted Therapies in Lung Cancer Live event!

#TargetedTherapies #LungCancer #Flaura2 #Osimeritinib